Multihance

Active Ingredient:: Gadobenate Dimeglumine
Origin:: EU

Multihance (Gadobenate Dimeglumine)

Q: What is Multihance used for?

Multihance is an injectable gadolinium‑based contrast agent used during magnetic resonance imaging to improve the visibility of structures in the brain, spinal cord, liver and cardiovascular system. It enhances the contrast between normal and abnormal tissues, helping radiologists detect lesions, assess vascular anatomy and evaluate organ function more accurately.

Q: How does gadobenate dimeglumine work?

Gadobenate dimeglumine is a paramagnetic chelate that shortens the T1 relaxation time of nearby water protons. After intravenous administration it distributes in the extracellular space and transiently binds to serum albumin, which raises its relaxivity. The resulting increase in signal intensity on T1‑weighted MRI sequences makes tissues appear brighter, facilitating detailed imaging.

Q: What is the usual dose of Multihance?

The dose of Multihance is determined by the prescribing physician based on the patient’s weight, renal function and the specific MRI protocol. Typical dosing follows the manufacturer’s recommendations, but exact amounts and injection rates are individualized for each examination and should be set by the qualified healthcare professional.

Q: Is Multihance safe during pregnancy or breastfeeding?

Safety data for gadobenate dimeglumine in pregnancy and lactation are limited. The agent should only be used when clearly needed and when the potential diagnostic benefit outweighs any possible risk to the fetus or infant. Physicians should discuss the risk‑benefit profile with the patient and consider alternative imaging strategies when appropriate.

Q: How do I order Multihance from GNH India?

To order Multihance, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Q: How does Multihance compare with other gadolinium contrast agents?

Multihance (gadobenate dimeglumine) has higher relaxivity than many conventional gadolinium agents because of its partial albumin binding, which can produce stronger signal enhancement at lower doses. This property may allow improved lesion detection, especially in liver and cardiovascular imaging, while maintaining a safety profile comparable to other agents when used according to guidelines.

Q: What are the storage and handling requirements for Multihance?

Multihance should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The vial should remain in its original packaging until use to maintain sterility. If the product reaches room temperature, it may be used within the time frame specified by the manufacturer, but it should be returned to refrigeration promptly.

Q: How is Multihance administered?

Multihance is administered by intravenous injection, typically using a power injector to deliver a controlled bolus followed by a saline flush. The injection rate and volume are selected according to the imaging protocol and patient characteristics. Administration is performed by trained healthcare personnel in a setting equipped for emergency management of potential adverse reactions.

Q: What are the most serious risks associated with Multihance?

The most serious risks include nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment, severe allergic reactions such as anaphylaxis, and cardiovascular events like hypotension or cardiac arrest occurring shortly after injection. Prompt recognition and treatment of these reactions are essential, and patients with high risk should be carefully screened before administration.

Q: Who should not receive Multihance?

Multihance should be avoided in patients with known hypersensitivity to gadolinium‑based agents, those with severe renal dysfunction (eGFR <30 mL/min/1.73 m²) due to the risk of NSF, and in individuals who have experienced a prior severe allergic reaction to any contrast medium. Caution is also advised for pregnant or lactating women unless the diagnostic benefit justifies potential risk.

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium‑based contrast agent presented as an injectable solution for intravenous use. It shortens T1 relaxation times, thereby increasing signal intensity on magnetic resonance imaging and is employed to improve visualization of the central nervous system, liver and cardiovascular structures.

GNH India supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, tertiary care centers and imaging facilities worldwide, with regulatory‑approved quality systems. Our distribution network ensures timely delivery and compliance with local import requirements.

Manufacturer / TM Owner

Bracco Imaging Deutschland Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Multihance is a gadolinium‑based contrast agent used in magnetic resonance imaging to enhance visualization of specific organ systems.

Central nervous system imaging: improves lesion detection and anatomical detail in brain and spinal cord MRI.
Liver imaging: enhances lesion conspicuity and vascular phase assessment in hepatic MRI.
Cardiovascular imaging: provides clearer delineation of cardiac chambers, vessels and perfusion during MRI studies.

How It Works

Gadobenate dimeglumine is a paramagnetic gadolinium chelate that shortens the longitudinal (T1) relaxation time of nearby water protons. After intravenous injection, the chelate distributes in the extracellular space and transiently binds to serum albumin, increasing its relaxivity. The resulting signal amplification on T1‑weighted sequences improves tissue contrast during MRI examinations. Its rapid renal clearance allows for short imaging windows while minimizing systemic exposure.

Side Effects

Adverse reactions to Multihance may range from mild, transient events to rare but serious conditions.

Common Side Effects

Nausea: mild, transient feeling of queasiness.
Headache: temporary discomfort following injection.
Injection site pain: brief soreness or burning at the catheter site.
Warm sensation: fleeting feeling of warmth or metallic taste.
Vomiting: occasional episodes after injection.
Dizziness: brief light‑headedness.

Serious or Rare Side Effects

Nephrogenic systemic fibrosis (NSF): a fibrotic disorder in patients with severe renal impairment.
Severe allergic reaction: anaphylaxis or angioedema requiring immediate medical intervention.
Cardiovascular collapse: hypotension or cardiac arrest occurring shortly after administration.
Gadolinium retention: long‑term deposition in brain or bone tissues, of uncertain clinical significance.

Precautions & Warnings

Prior to using Multihance, several safety considerations should be evaluated to minimize risk.

Assess renal function: evaluate eGFR and avoid use in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²).
Review allergy history: contraindicated in individuals with known hypersensitivity to gadolinium agents.
Pregnancy and lactation: use only if essential, as safety data are limited.
Pediatric use: dose adjustment and careful monitoring are required for children.
Concomitant nephrotoxic drugs: consider reducing exposure to agents that may worsen renal function.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Multihance may interact with other medicines or conditions that affect renal clearance or immune response.

Major Interactions (Avoid)

Renal toxic agents (e.g., high‑dose NSAIDs, aminoglycosides): increase risk of renal impairment and NSF.
Chelating therapy (e.g., deferoxamine): may bind gadolinium and reduce imaging efficacy.

Moderate Interactions (Monitor Closely)

Beta‑blockers: may blunt hemodynamic changes during injection.
Hydration protocols: adequate fluid administration can mitigate renal risk and should be coordinated.
Calcium channel blockers: occasional reports of altered contrast distribution; monitor patient response.

Frequently Asked Questions

Multihance is an injectable gadolinium‑based contrast agent used during magnetic resonance imaging to improve the visibility of structures in the brain, spinal cord, liver and cardiovascular system. It enhances the contrast between normal and abnormal tissues, helping radiologists detect lesions, assess vascular anatomy and evaluate organ function more accurately.

Gadobenate dimeglumine is a paramagnetic chelate that shortens the T1 relaxation time of nearby water protons. After intravenous administration it distributes in the extracellular space and transiently binds to serum albumin, which raises its relaxivity. The resulting increase in signal intensity on T1‑weighted MRI sequences makes tissues appear brighter, facilitating detailed imaging.

The dose of Multihance is determined by the prescribing physician based on the patient’s weight, renal function and the specific MRI protocol. Typical dosing follows the manufacturer’s recommendations, but exact amounts and injection rates are individualized for each examination and should be set by the qualified healthcare professional.

Safety data for gadobenate dimeglumine in pregnancy and lactation are limited. The agent should only be used when clearly needed and when the potential diagnostic benefit outweighs any possible risk to the fetus or infant. Physicians should discuss the risk‑benefit profile with the patient and consider alternative imaging strategies when appropriate.

To order Multihance, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Multihance (gadobenate dimeglumine) has higher relaxivity than many conventional gadolinium agents because of its partial albumin binding, which can produce stronger signal enhancement at lower doses. This property may allow improved lesion detection, especially in liver and cardiovascular imaging, while maintaining a safety profile comparable to other agents when used according to guidelines.

Multihance should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The vial should remain in its original packaging until use to maintain sterility. If the product reaches room temperature, it may be used within the time frame specified by the manufacturer, but it should be returned to refrigeration promptly.

Multihance is administered by intravenous injection, typically using a power injector to deliver a controlled bolus followed by a saline flush. The injection rate and volume are selected according to the imaging protocol and patient characteristics. Administration is performed by trained healthcare personnel in a setting equipped for emergency management of potential adverse reactions.

The most serious risks include nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment, severe allergic reactions such as anaphylaxis, and cardiovascular events like hypotension or cardiac arrest occurring shortly after injection. Prompt recognition and treatment of these reactions are essential, and patients with high risk should be carefully screened before administration.

Multihance should be avoided in patients with known hypersensitivity to gadolinium‑based agents, those with severe renal dysfunction (eGFR <30 mL/min/1.73 m²) due to the risk of NSF, and in individuals who have experienced a prior severe allergic reaction to any contrast medium. Caution is also advised for pregnant or lactating women unless the diagnostic benefit justifies potential risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.